GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Slc51a | decreases expression | ISO | Slc51a (Mus musculus) | 6480464 | CTD | Deoxycholic Acid results in decreased expression of SLC51A mRNA | PMID:21914718 | Slc51a | increases expression | ISO | Slc51a (Mus musculus) | 6480464 | CTD | Deoxycholic Acid results in increased expression of SLC51A mRNA | PMID:25582706 | Slc51a | increases expression | ISO | SLC51A (Homo sapiens) | 6480464 | CTD | Deoxycholic Acid results in increased expression of SLC51A; Deoxycholic Acid results in increased expression of SLC51A mRNA | PMID:22268002 PMID:25055961 | Slc51a | multiple interactions | ISO | Slc51a (Mus musculus) | 6480464 | CTD | SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of SLC51A mRNA] | PMID:21914718 | Slc51a | multiple interactions | ISO | SLC51A (Homo sapiens) | 6480464 | CTD | [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA | PMID:32152650 | |
Go Back to source page | Continue to Ontology report |